HIF1A and central nervous system cancer: PX‐478, a HIF‐1α inhibitor, has been shown to inhibit the protein expression level and transcriptional activity of HIF‐1α, thereby exhibiting effective antitumour activity in various tumours, including nonsmall cell lung cancer, glioma and pancreatic cancer.59, 60, 61